Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgane Denis

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 13, 2026
Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse modelCarla Dib, Jack A Queenan, Hana Willner, et al.
Cancer Immunology Research|June 9, 2022
In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 TherapiesMorgane Denis, Chloé Grasselly, Pierre-Antoine Choffour, et al.
Frontiers in Immunology|May 24, 2023
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical modelsKamel Chettab, Chantel Fitzsimmons, Alexey Novikov, et al.
Nature Communications|July 31, 2025
GFP-on mouse model for interrogation of in vivo gene editingCarla Dib, Jack A Queenan, Leah Swartzrock, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 13, 2026
Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse modelCarla Dib, Jack A Queenan, Hana Willner, et al.
Cancer Immunology Research|June 9, 2022
In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 TherapiesMorgane Denis, Chloé Grasselly, Pierre-Antoine Choffour, et al.
Frontiers in Immunology|May 24, 2023
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical modelsKamel Chettab, Chantel Fitzsimmons, Alexey Novikov, et al.
Nature Communications|July 31, 2025
GFP-on mouse model for interrogation of in vivo gene editingCarla Dib, Jack A Queenan, Leah Swartzrock, et al.
Pageof 2